DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

This early-phase study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to first treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal w…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug…

This study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…

This study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…

This study examined genetic changes in 555 patients with aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma. Researchers used a technique called FISH to look for specific gene rearrangements. The goal was to see if these genetic markers could help classify tumors …